TY - JOUR
T1 - Evaluation of mediators associated with the inflammatory response in prostate cancer patients undergoing radiotherapy
AU - Bedini, Nice
AU - Cicchetti, Alessandro
AU - Palorini, Federica
AU - Magnani, Tiziana
AU - Zuco, Valentina
AU - Pennati, Marzia
AU - Campi, Elisa
AU - Allavena, Paola
AU - Pesce, Samantha
AU - Villa, Sergio
AU - Avuzzi, Barbara
AU - Morlino, Sara
AU - Visentin, Maria Emanuela
AU - Zaffaroni, Nadia
AU - Rancati, Tiziana
AU - Valdagni, Riccardo
PY - 2018/1/1
Y1 - 2018/1/1
N2 - A recent "hot topic" in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence of abdominal surgery before radiotherapy. The exact mechanism is unclear. Our working hypothesis was that a previous surgery may influence plasma level of inflammatory molecules and this might result in enhanced radiosensitivity. We here present results on the feasibility of monitoring the expression of inflammatory molecules during radiotherapy. Plasma levels of a panel of soluble mediators associated with the inflammatory response were measured in prostate cancer patients undergoing radical radiotherapy. We measured 3 cytokines (IL-1b, IL-6, and TNF alpha), 2 chemokines (CCL2 and CXCL8), and the long pentraxin PTX3. 20 patients were enrolled in this feasibility evaluation. All patients were treated with IMRT at 78 Gy. 3/20 patients reported grade 2 acute rectal toxicity, while 4/20 were scored as grade 2 late toxicity. CCL2 was the most interesting marker showing significant increase during and after radiotherapy. CCL2 levels at radiotherapy end could be modelled using linear regression including basal CCL2, age, surgery, hypertension, and use of anticoagulants. The 4 patients with late toxicity had CCL2 values at radiotherapy end above the median value. This trial is registered with ISRCTN64979094.
AB - A recent "hot topic" in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence of abdominal surgery before radiotherapy. The exact mechanism is unclear. Our working hypothesis was that a previous surgery may influence plasma level of inflammatory molecules and this might result in enhanced radiosensitivity. We here present results on the feasibility of monitoring the expression of inflammatory molecules during radiotherapy. Plasma levels of a panel of soluble mediators associated with the inflammatory response were measured in prostate cancer patients undergoing radical radiotherapy. We measured 3 cytokines (IL-1b, IL-6, and TNF alpha), 2 chemokines (CCL2 and CXCL8), and the long pentraxin PTX3. 20 patients were enrolled in this feasibility evaluation. All patients were treated with IMRT at 78 Gy. 3/20 patients reported grade 2 acute rectal toxicity, while 4/20 were scored as grade 2 late toxicity. CCL2 was the most interesting marker showing significant increase during and after radiotherapy. CCL2 levels at radiotherapy end could be modelled using linear regression including basal CCL2, age, surgery, hypertension, and use of anticoagulants. The 4 patients with late toxicity had CCL2 values at radiotherapy end above the median value. This trial is registered with ISRCTN64979094.
UR - http://www.scopus.com/inward/record.url?scp=85048604844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048604844&partnerID=8YFLogxK
U2 - 10.1155/2018/9128128
DO - 10.1155/2018/9128128
M3 - Article
C2 - 29682101
AN - SCOPUS:85048604844
VL - 2018
JO - Disease Markers
JF - Disease Markers
SN - 0278-0240
M1 - 9128128
ER -